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Substantialprogresshasbeenmadeinthedevelopmentofnovelgenetherapystrategiesforcentralnervoussystem(CNS)disorders
in recent years. However, unregulated transgene expression is a signiﬁcant issue limiting human applications due to the potential
side eﬀects from excessive levels of transgenic protein that indiscriminately aﬀect both diseased and nondiseased cells. Gene
regulation systems are a tool by which tight tissue-speciﬁc and temporal regulation of transgene expression may be achieved.
This review covers the features of ideal regulatory systems and summarises the mechanics of current exogenous and endogenous
gene regulation systems and their utility in the CNS.
1.Introduction
Recent years have seen a plethora of potential gene therapy
strategies for central nervous system (CNS) disorders. One
of the major challenges gene therapy applications face
clinically is the ability to control the level of expression or
silencing of therapeutic genes in order to provide a balance
between therapeutic eﬃcacy and nonspeciﬁc toxicity due to
overexpression of therapeutic protein or RNA interference-
basedsequences.Thus,theabilitytoregulategeneexpression
isessentialasitreducesthelikelihoodofpotentiallyinitiating
adverse events in patients. Although genes may be regulated
at either the translational or posttranscriptional level, great-
est success in gene regulation has been at the transcriptional
level and as such gene regulation systems at a transcriptional
level is the focus of this review. There are two classes of gene
regulation systems—exogenously controlled gene regulation
systems, which rely on an external factor (usually the admin-
istration of a drug) to turn transgene expression on or oﬀ,
and endogenously controlled gene expression systems that
rely on physiological stimuli to control transgene expression.
This review covers the characteristics of an ideal regulatory
system and summarises the mechanics of current gene
regulation systems and their application to CNS disorders.
2.What Arethe Characteristicsof
a Good Gene Regulation System?
In order to be clinically eﬀective, it has been proposed that
regulatory systems should possess the following characteris-
tics [1]:
(i) Exhibit low basal expression. In the “oﬀ” state, trans-
gene expression should be subphysiological. This
wouldbecrucialintheeventofanadversereactionto
the treatment.
(ii) Be positively induced. Induction of gene expression
should be positive, through the presence, rather than
the absence of an inducing stimulus so that patients
can discontinue drug therapy when treatment is no
longer required. In the case of endogenously con-
trolled systems, this would enable transgene expres-
sion to be repressed when the treatment is no longer
required.
(iii) Transgenic protein levels should lie between therapeutic
indices. Transgene expression should be inducible to
physiological levels to enable a therapeutic outcome.2 Neurology Research International
(iv) Be regulatable over a wide dose range. Responsiveness
toawidedoserangeoftheinducerwillenablegreater
precision in titrating transgene expression levels to
optimal therapeutic levels.
(v) Exert no pleiotropic eﬀects. Ideally the transgene
wouldproducethedesiredeﬀectonitscellulartargets
and not have an eﬀect on any other phenotypic traits;
however, this may not be controllable.
(vi) Beofhumanorigin.Theriskofimmunogenicityisde-
creased when components of regulatory systems are
of human origin.
(vii) Not aﬀectendogenousgeneexpression. Components of
the regulatory system such as transcription factors or
small molecule inducers should not have pleiotropic
eﬀects in mammalian cells and aﬀect expression of
endogenous genes.
(viii) Be region or cell speciﬁc. It would be eﬃcacious to
limit transgene expression to speciﬁc regions or cell
types that require it.
(ix) Transgene expression should be induced and repressed
as quickly as possible. This would enable maximal
physiological beneﬁt to be obtained and would (i) re-
duce the likelihood of toxic overexpression of trans-
gene in cells that no longer require it and (ii) enable
discontinuation of adverse eﬀects to the treatment in
a timely manner.
3.ExogenouslyRegulatedGene
ExpressionSystems
Exogenously regulated systems are the most well-character-
ised class of regulation systems, and substantial progress has
been made on their design and optimization in recent years.
This section covers the mechanics and utility of popular
systems for CNS gene therapy (see Table 1 for a summary of
in vivo applications).
3.1. Tetracycline Regulated Systems. The tetracycline regulat-
ed gene expression system developed by Gossen and Bujard
[2] is the most widely used gene regulation system. There are
two variants: the Tet-Oﬀ system was the ﬁrst to be developed
[2], followed by the Tet-On system [3], that has now become
more popular. The Tet-Oﬀ system is negatively controlled
and relies on tetracycline to deactivate expression, whereas
the Tet-ON system relies on tetracycline to activate gene
expression.
Transactivators (tTAs) are constitutively produced by a
cell or tissue-speciﬁc promoter through fusion of a viral
protein (VP16) domain to the tet-repressor protein. In the
Tet-Oﬀ system, when doxycycline, a tetracycline derivate is
present, the transactivators are unable to bind to their target,
a tet-operator sequence upstream of a cytomegalovirus
(CMV) promoter (termed the tetracycline response element
[TRE]) that drives transgene expression. Conversely, in the
absence of doxycycline, the tTAs bind to the TRE, driving
transgene expression (Figure 1(a)). The Tet-On system was
developed by inducing random mutations in the tTA of
the Tet-Oﬀ system [3]. One of the mutations led to a four
amino-acid change that resulted in a protein with opposite
function. These mutant proteins, termed reverse transac-
tivators (rtTAs), drive transgene expression by activating
the TRE only in the presence of doxycycline. Absence of
doxycycline results in the inhibition of transgene expression
(Figure 1(b)).
Tetracycline-based regulation systems are a good candi-
dateforgenetherapyapplicationsduetotheirextensivechar-
acterization and the fact that tetracycline and its derivatives
have been used clinically for decades. The majority of CNS
applications involving this system have used viral vectors
for construct delivery, of which adenoassociated viral (AAV)
vectors have been the most popular.
Haberman and colleagues were the ﬁrst to demonstrate
that AAV vectors coupled with the Tet-Oﬀ system can be
used to produce regulated, long-term gene expression in the
rat brain [4]. A dual cassette was constructed with the gene-
encoding enhanced green ﬂuorescent protein (GFP) under
the control of the TRE and a gene-encoding modiﬁed tTAs
on the same construct. The tTAs and gene of interest were
placed under the same transcriptional control to limit
leakiness and decrease the likelihood of cytotoxic eﬀects of
tTAs. This method was dependent on the activity of the
CMV promoter to produce a small amount of tTA protein to
initiate a feedback loop to enhance tTA and therefore trans-
gene expression. AAV-expressing constructs were injected
into the inferior colliculus, and transgene regulation was
achieved through the presence or absence of doxycycline in
the drinking water. Since this pioneering study, a number of
other groups have incorporated the tetracycline system into
viral vectors for both in vitro and in vivo applications. There
are ﬁve main arrangements that have been used, using either
one or two vectors (Figure 2).
AAV vectors have been the most widely used, followed by
adenoviral vectors [6, 12] and lentiviral (LV) vectors [13].
Single vector designs limit the size of the transgene that
can be incorporated; AAV vectors have a maximum capacity
of approximately 5.0kb, leaving approximately 2.0–2.5kb
for transgenes. However, the tetracycline system is small
in comparison to other systems, and some groups have
managed to incorporate multiple transgenes into a single-
vector construct [5, 9, 11]. A two-vector design, where the
tTA/rtTAs are encoded on a separate vector, enables trans-
genes of up to 4.0kb to be incorporated into a single AAV
vector. This design requires both vectors to transduce each
cell in order to be functional, so the ratio of vectors
must be tightly controlled. Single-vector designs that utilize
constitutive promoters such as CMV suﬀer from interference
between the tet-operator sequence and the CMV promoter,
leading to high basal transgene expression. This issue has
been addressed by placing the tTA/rtTAs under the control
of a weak minimal promoter such as the thymidine kinase
promoter [8] or the tetO sequence itself [14, 15].
Although it is diﬃcult to make direct comparisons due
to the number of diﬀerent construct compositions used, in
terms of kinetics, high inducibility and repression has been
achieved both in vitro and in vivo; however, there is still
some residual transgene expression present in the “oﬀ” state.Neurology Research International 3
Table 1: Summary of use of gene regulation systems for in vivo CNS applications.
Regulation
system (VC∗) Stimuli/dose Delivery vehicle Species Transgene Comments [ref]
Tet-Oﬀ (VC1) Dox (300μg/mL and
2mg/mL) AAV Rat GFP Some leakiness. No further transgene repression
by increasing dox dosage [4].
Tet-On (VC2) Dox (6g/kg) AAV Rat EGFP No repression or basal expression data [5].
Tet-On (VC1 & 2) Dox (2mg/mL) Ad Rat LacZ Negligible expression following dox removal [6].
Tet-Oﬀ (VC1) Dox AAV Rat GDNF
Undetectable transgene levels at serum dox
levels below those required for antimicrobial
activity [7].
Tet-Oﬀ (VC2) Dox (300μg/mL) AAV Rat EGFP Low basal expression with addition of insulator
sequences [9].
Tet-On (VC2) Dox (600μg/mL) AAV Rat GDNF Some basal expression [11].
Tet-Oﬀ (VC3) Dox (2mg/mL) Ad Rat Caspase-9 & EGFP Variable repression achieved; transgene
dependent [13].
Tet-On (VC1) Dox (2mg/mL) LV Rat Luciferase Low basal expression [19].
Rapamycin Rapamycin
(10mg/kg) AAV Rat hAADC
Robust phenotypic response in 6-OHDA model.
Low basal expression without phenotypic eﬀect
[25].
Rapamycin AP21967 (1mL/kg) LV Mouse GFP & GDNF No basal expression [28].
RU486 RU486 (25mg/kg) HSV Rat LacZ Very low basal expression [31].
HRE
30min hypoxia in a
3% O2 hypoxic
chamber
Ad Mouse Luciferase No transgene expression under normoxic
conditions [36].
HRE 60min MCAO Ad Mouse BDNF & EGFP
Neuroprotection & phenotypic changes seen. No
comparison with unregulated transgene
expression [37].
HRE 45min MCAO AAV Mouse VEGF or LacZ Angiogenesis seen. No transgene expression
under nonischemic conditions [39].
HRE Spinal cord
contusion injury
Naked plasmid
injection Rat VEGF Locomotor recovery compared to uninjected
controls [42].
HRE Spinal cord
contusion injury
Naked plasmid
injection Rat Luciferase Higher transgene expression in injured
compared to normal spinal cord [44].
HRE Spinal cord
contusion injury
Ex vivo stem
cell therapy Rat Luciferase Low transgene expression in normal spinal cord
[45].
∗V C ,V e c t o rC o n ﬁ g u r a t i o n( s e eFigure 2); Dox, doxycycline; GFP, Green Fluorescent Protein; EGFP, Enhanced Green Fluorescent Protein.
The induction of transgene expression should be as quick as
possible in order to facilitate maximal physiological beneﬁt.
Maximal transgene expression has been reported within 48h
in vitro [9, 11]. Additionally, transgene expression can be
induced in vivo as early as 6 days [6], with levels as high as 80
and 204-fold [5, 8]. Whether the time to induction reported
inthesestudiesis acceptablewilldependon thedisease being
treated. Neurodegenerative disorders progress slowly so the
forementioned induction times are probably acceptable.
However, acute conditions such as stroke necessitate prompt
action so these time periods would not be ideal.
Repression can be achieved quite rapidly—as early as 2
days in vitro [11] and 3–10 days in vivo [5, 9]. Whether
this time period is satisfactory will depend on the toxicity
proﬁle of the transgene being expressed and/or the severity
and nature any adverse reaction to the treatment. Tight
regional distribution of transgene has been achieved in
the rat brain using the AAV/Tet-On system, compared to
the constitutively active AAV/CMV system [16]. To ensure
cell-speciﬁc transgene expression, the CMV promoter has
been replaced with the neuron-speciﬁc enolase (NSE) pro-
moter [13]. Additionally, physiologically relevant levels of
transgenic protein are being produced in the brain—of
particular note is a study conducted by Manfredsson and
colleagues who used an AAV/Tet-Oﬀ system to express
glial cell line-derived neurotrophic factor at levels exceeding
those required for eﬃcacy in a 6-hydroxydopamine model
of Parkinson’s disease [7]. More recently, doxycycline-
controlled expression of cell-speciﬁc microRNA sequences
that mediate RNA interference-based gene silencing has also4 Neurology Research International
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Figure 1: Mechanics of tetracycline regulated systems. A constitutively active promoter drives expression of tetracycline transactivators
(tTAs) or reverse tetracycline transactivators (rtTAs). (a) Tet-Oﬀ system. tTAs are able to bind to the tet-operator sequence (tetO) in the
absence, but not in the presence of doxycycline (dox) to drive transgene expression. (b) Tet-On system. rtTAs are able to bind to the TRE
in the presence, but not in the absence of dox to drive transgene expression. tetR: tetracycline repressor; VP16: viral protein 16; CMV:
cytomegalovirus.
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Figure 2: Diﬀerent conﬁgurations the tetracycline system has been incorporated into viral vectors for use in the brain. (1) Two right-facing
cistrons direct transactivator and transgene expression in a single vector [4–7]. (2) One bidirectional promoter driving expression of the
transgene and transactivators in a single construct [5, 6, 8–10]. (3) Two vectors are used: one bidirectional construct directing expression of
two transgenes and one driving expression of transactivators [11, 12]. ITR: inverted terminal repeats; PolyA: polyadenylation signal; TetO:
tetracycline operator sequence; CMV: cytomegalovirus; tTA: tetracycline transactivator; rtTA: reverse tetracycline transactivator.
been demonstrated broadening the utility of this system in
regulating another potential class of therapeutic molecule
[17].
In order to attain adequate dose-responsive control and
limit the likelihood of toxic overexpression of the transgene,
it is desirable to use the lowest possible concentration of
doxycycline. Although doxycycline has a high serum uptake
and clearance, it has a considerably slow tissue clearance.
This means that transgene activation is an inherently faster
process than repression. Consequently, the Tet-On system
would be more suitable for conditions with acute onset
such as stroke, where transgene activation is required rap-
idly; however, this would be accompanied with the risks
mentioned above. For all other applications, the Tet-Oﬀ
system would be a safer option but would require life-
long doxycycline administration following cessation of the
treatment. Moreover, it would be important to establish that
long-term expression of tTA protein also causes no toxicity.
Of note, no humoral immune response against the tTA
protein was found following intrastriatal infusion of a tet-
oﬀ AAV vector expressing hAADC or hGDNF suggesting
that these might be safer vectors for Parkinson’s disease gene
therapy [18].
There are two main issues that are thought to contribute
to the leakiness of the tetracycline system in the oﬀ state.
The ﬁrst is that the transactivators retain some ability toNeurology Research International 5
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Figure 3: Schematic of the rapamycin regulation system. The constitutively active human cytomegalovirus (hCMV) promoter drives
expression of two fusion transcription factors. (Top left) A transcription factor consisting of three copies of the FKBP protein fused to a
ZFHD1 DNA binding domain. (Top right) A transcription factor consisting of a FRAP protein with a p65 activation domain. Rapamycin
enables dimerization of the transcription factors, with enable binding to 12xZFHD1 binding sites and activation, respectively, driving
expression of a transgene upstream of a minimal CMV promoter. ZFHD1: zinc ﬁnger homeodomain-1; FKBP: FK-binding protein; FRAP:
FKBP-rapamycin associated protein [23].
bind to the TRE in the uninduced state, and the second
is the close proximity of the TRE to the inverted terminal
repeats, which possess enhancer activity [19]. Considerable
research has been undertaken to reduce the likelihood
of transactivators binding to tet-operator sequence under
basal conditions. Urlinger and colleagues have developed
two systems: one involved the identiﬁcation of novel rtTAs
through PCR mutagenesis of the tetracycline repressor
protein. To do this, PCR of original rtTAs was conducted
under conditions designed to induce misincorporation
of nucleotides. Compared to the original rtTA, modiﬁed
rtTA was associated with considerably lower background
expression, while its activation potential was nearly the
same as the unmodiﬁed rtTA [20]. The second strategy
involved producing a transcriptional silencer which binds to
promoters responsive to rtTA and blocks their activation in
the absence of doxycycline. In the presence of doxycycline,
transcriptional silencers are unable to bind to the promoter,
relieving transcriptional repression and promoting binding
of rtTA which enables transgene expression. Combining the
forementioned systems in a bicistronic construct reduced
basal expression 6-fold compared to expression of the novel
transactivators alone; however, activation was approximately
3-fold less potent with these bicistronic constructs compared
to their monocistronic counterparts [21].
To circumvent the issue of inverted terminal repeat prox-
imity, Fitzsimons and colleagues have inserted insulators
ﬂanking the regulation system. While the leakiness was only
partially ameliorated in vitro, repression was increased from
40to204-foldinvivo[8].Abidirectionalcomposition,where
the TRE is located in the middle of the construct, maximizes
the distance from the inverted terminal repeats and appears
to produce the least amount of basal expression; however,
there is still a considerable amount of transgene expression
present.Otherhypothesestoexplainbasalexpressioninclude
the integration of transgenes at unsuitable chromosomal
sites or close proximity of the transgene to the element
driving transactivator expression [22].
These ﬁndings suggest that vector-mediated delivery of
tetracycline-based regulatory systems shows considerable
promise in the treatment of CNS disorders; however, addi-
tional studies are required to further optimize this system to
reduce basal expression whilst maintaining high induction
levels.
3.2. Rapamycin-Regulated Systems. Designed by Rivera and
colleagues [23], the rapamycin-regulated gene regulation
system relies on the interaction between two transcription
factors, one incorporating a DNA-binding domain and the
other a DNA activation domain. Each of the transcrip-
tion factors also contains a heterologous ligand-binding
domain that enables their interaction in the presence of the
dimerizing drug rapamycin to drive transgene expression.
DNA binding is facilitated through the human CMV pro-
moter driven production of a zinc ﬁnger homeodomain-
1 (ZFHD1) DNA-binding domain fused to three copies
of the FK-binding protein (FKBP). Transgene expression
is achieved in the presence of rapamycin, which induces
dimerization of this DNA-binding protein with a fusion pro-
tein consisting of the FKBP-rapamycin-associated protein 1
(FRAP) fused to the NFκB p65 activation domain (Figure 3).
Due to the size of this system, two viral vectors are
required for delivery of all the components. A 1:1 ratio of
transcriptionfactorvectortotransgenevectorissuﬃcientfor6 Neurology Research International
high induction and low basal transgene expression [24]. This
system has many of the properties required for use clinically.
It is characterized by a high induction ratio, low basal
expression, and is composed entirely of human proteins. Ad-
ditionally, rapamycin can be administered orally and has a
pharmacokinetic proﬁle that has been widely studied. The
primary issue with this system was that rapamycin functions
as an immunosuppressant through blocking FRAP activity
[25] and inhibiting progression through the cell cycle at con-
centrations required for gene regulation. Rapamycin analogs
(“rapalogs”) have since been engineered by adding sub-
stituents which prevent binding to FRAP [26].
Only a few studies have tested this system in the CNS
using viral vector delivery thus far, leaving this ﬁeld large-
ly uncharacterized. Rapalogs have been used to increase
expression of human aromatic L-amino acid decarboxylase
(hAADC), the enzyme that converts levodopa to dopamine
in the striatum of a rodent model of Parkinson’s disease
(PD) [24]. AAV vectors were coinfused, one expressing
the transcription factors and one encoding the hAADC
transgene downstream from a rapamycin-inducible pro-
moter. Rapamycin-induced robust rotational behaviour in
thepresenceoflowdosesoflevodopaandalthoughlowlevels
of hAADC were observed in the absence of rapamycin, these
levels were not signiﬁcant enough to induce a behavioural
response. This study demonstrated for the ﬁrst time that
rapamycin is able to eﬃciently cross the blood-brain barrier
and induce expression of recombinant protein at levels that
have a signiﬁcant phenotypic eﬀect, and in a suﬃciently
regulated manner. More recently LV-mediated transfer of a
rapalog-controlled system has been used to tightly regulate
expression of glial cell line-derived neurotrophic factor and
GFP in the striatum of mice [27]. It is yet to be established
whetherLVvectorscanbeusedtoproducerecombinantpro-
teins at physiologically relevant levels using the rapamycin
system. Further studies are required to gain a thorough dose-
responsive proﬁle of rapalogs in the CNS and to explore
the possibility of using cell-speciﬁc promoters such as the
tyrosine hydroxylase or NSE promoters for more targeted
transgene expression. Additionally, given that the proteins
in this system are of human origin, it would be prudent to
investigate the possible eﬀects of these chimeric proteins on
endogenous gene expression in the brain.
3.3. RU486-Regulated System. The RU486 system is con-
ceptually similar to the rapamycin system; it relies on the
drug RU486 to activate a chimeric transcription factor that
drives transgene expression. A chimeric regulator protein
is constitutively produced, consisting of the DNA-binding
domain of the yeast transcription factor Gal4 (Gal4 DBD),
a truncated progesterone ligand-binding domain (PRLBD),
and a VP16 activation domain. In the presence of RU486, the
regulator protein is activated, enabling binding to the target
construct consisting of 17x4Gal4 DNA-binding sites and a
minimalpromoter(suchasTATA)upstreamofthetransgene
(Figure 4). Tissue-speciﬁc promoters can be used to produce
the transcription factor [28].
The RU486 system has been incorporated into adenovi-
ral, LV, and herpes simplex viral (HSV) vectors but has only
been tested in vivo in one study thus far. It is similar in
size to the tetracycline regulated system and may be incor-
porated into one or two vectors (in a 1:1 ratio [29]) depend-
ing on the size of the transgene to be expressed. The in vivo
study involved using a single HSV viral vector to deliver
a bicistronic construct expressing both the LacZ reporter
gene under the control of a minimal Gal4 promoter and
the regulator protein under the control of a minimal hCMV
promoter to the rat hippocampus. Upon induction via
intraperitoneal injection of RU486, β-galactosidase levels
increased 150-fold compared to basal levels, which were
extremely low [30]. Interestingly, results from in vitro studies
involving viral vectors have not been as consistent. Molin
and colleagues compared the eﬃcacy of the RU486 system
with the Tet-On system when packaged into Ad vectors.
A two-vector system was used, with one vector encoding
the reporter gene chloramphenicol acetyltransferase (CAT)
and the other encoding the respective transcription factors.
While the RU486 system-induced CAT expression to high
levels in three other cell lines, it failed to induce suﬃcient
CAT levels in the NIH 3T3 cell line. Given that the Tet-
On system worked well in this cell line, it is likely that this
failure was due to the inability of RU486 to activate the
progesterone receptor in this cell type, rather than ineﬃcient
vector uptake [31]. Additionally, a more recent in vitro study
involving LV delivery of the RU486 system showed robust
induction of red ﬂuorescent protein and GFP, but not of
antitrypsin protein [29]. The authors suggest that the RU486
system may function diﬀerently when expressing secretable
versus intracellular proteins. Relatively low concentrations
of RU486 have been used to achieve robust transgene
expression in vitro (10−7–10−8 M) [29, 30]. However, the
dose given to induce transgene expression in vivo (25mg/kg)
exceeds the dose used clinically as an antiprogesterone
therapy (10mg/kg). Given this data, a considerable amount
of additional investigation needs to be undertaken before
the RU486 system can be used clinically for the treatment
of CNS disorders. Speciﬁcally, information is required on
the dose-responsiveness of RU486 in vivo and the time
required for transgene repression following the removal of
RU486. Lastly, it will be imperative to determine whether the
RU486 system can produce physiologically relevant levels of
transgenicproteininthebrain,asnophenotypicstudieshave
been undertaken.
4.Endogenously ControlledGene
ExpressionSystems
Physiologically responsive gene expression systems incor-
porate negative feedback loops, where the recombinant
protein shuts oﬀ its own production in response to the
presence or absence of a physiological signal. Since the
focus of this review is gene regulation in the CNS, only
those physiologically regulated systems with potential for
application to the CNS will be covered (see Table 1 for a
summary of in vivo applications); however, it should be
noted that there has been robust success in the ﬁeld of
glucose-responsive control of insulin production [32, 33].Neurology Research International 7
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Figure 4: Schematic of the RU486 regulation system. A constitutively active promoter drives expression of a fusion protein consisting of a
VP16 activation domain, a Gal4 DNA-binding domain (DBD) and a progesterone ligand-binding domain (Prog LBD). Binding of RU486 to
the Prog LBD enables dimerization and binding to 4x Gal 4-binding sites upstream of a TATA box driving transgene expression [28]. Poly A,
poly adenylation signal.
4.1. Hypoxia-Regulated System. Oxygen deprivation or hyp-
oxia is a common feature of neuropathophysiological con-
ditions such as stroke and cerebral ischemia. The physio-
logical response to hypoxia includes induction of several
genes mediated by the transcription factor HIF1 (hypoxia-
inducible factor 1). HIF1 is composed of two subunits:
HIF1α and HIF1β. Under hypoxic conditions, HIF-1α is
produced and dimerizes with HIF-1β, which is constitutively
produced under normoxic conditions, forming HIF1, which
binds to hypoxia response elements (HREs) inducing tran-
scription of a downstream gene of interest. HIF1α levels
increase in neurons, astrocytes, ependymal, and possibly
endothelial cells in response to hypoxia in the brain [34].
In terms of a therapeutic strategy, hypoxia-regulated gene
expression is achieved by the insertion of multiple copies of
the HRE upstream of a promoter that drives transgene ex-
pression.
This system has been incorporated into viral vectors for
use in the brain and shows considerable promise as a strategy
for the treatment of cerebral ischemia. It is associated with
low transgene expression under normoxic conditions that is
inducible in a hypoxia-dependent manner in both in vitro
and in vivo models. Studies in mouse models of cerebral
ischemia have demonstrated increases in transgene levels of
approximately 17- [35] and 28-fold [36] following adenovi-
ral gene delivery. Whether or not these levels are suﬃcient
to be therapeutic depends on the candidate gene and the
duration of transgene expression. Expression levels of brain-
derived neurotrophic factor and vascular endothelial growth
factor were shown to be suﬃcient to elicit a phenotypic
response in mouse models of cerebral ischemia, by promot-
ing neuroprotection and angiogenesis, respectively [36–38].
Achievingarapidresponsewillbepivotalinaclinicalsetting;
however, information is lacking on the temporal nature of
transgeneexpressionusingthissystem.Transgeneexpression
has been reported as early as 12h following hypoxia in vivo
[36]; however, it is possible that this response might be
initiated at an earlier time point. Interestingly, in vitro trans-
gene expression has been reported at 3 hours in a serum
deprivation-induced model of hypoxia in PC12 cells [39].
Accordingly, it is important that transgene expression is
repressed in a timely manner after hypoxia to reduce the
likelihood of toxic overexpression of transgenic protein.
Shen and colleagues have demonstrated that transgenic
protein persists in the brain for 2 weeks after hypoxia [37];
however, the upper limit may be longer than this. Given
that activation and repression of transgene expression is
dependent on changes in oxygen (and thus HIF1α) levels, as
the duration and severity of hypoxia increases, there should
be a concomitant increase in transgene expression. Indeed,
a duration-dependent increase in transgene levels has been
demonstrated in PC12 cells following hypoxia treatment for
1, 3, 6, 9, 12, and 24h [39, 40]. Additionally, Huang and
colleagues have demonstrated a severity-dependent increase
in transgene expression following treatment with 0.1, 1, and
5% oxygen levels in PC12 cells [40].
Shen and colleagues have found that AAV vector delivery
ofthissystemresultsintransgeneexpressioninbothneurons
andastrocytes[37].Inordertofacilitateselectivetargetingof
neurons, neuron-speciﬁc promoters could be used; however,
studies thus far have only utilized minimal constitutively
active promoters. Interestingly, Hou and colleagues have
described a diﬀerent approach to neuronal targeting; they
have incorporated a neuron-restrictive silencer element into
the construct [35, 40]. The neuron-restrictive silencer ele-
ment is controlled by a factor that is only present in
nonneuronal cells [41]. Neuronal-speciﬁc targeting has been
achieved both in vitro and in vivo using this construct;
however, this has been at the expense of the induction ratio
[35].
While the majority of studies have used viral delivery
methods, Ha and colleagues have employed both naked8 Neurology Research International
plasmid injection and ex-vivo stem cell delivery to rat models
of spinal cord injury. Hypoxia-induced transgene expression
w a sd e m o n s t r a t e di nb o t hn e u r o n sa n da s t r o c y t e s[ 42–44].
Interestingly, these studies have injected the test constructs
immediately following the hypoxic insult while studies using
viral vectors have injected the constructs between 5 and 7
dayspriortohypoxia toenableadequatetransduction.Given
that minimizing the time to transgene expression is key to
the development of successful therapies for cerebral ischemia
using this system, there remains a need for these studies to be
conductedinamoreclinicallyrelevantmanner.Additionally,
since HIF-1α is an important regulatory molecule involved
in number of downstream gene networks under normoxic
conditions [45], gene expression proﬁling needs to be
conducted before HRE-regulated treatments can be widely
used.
5. Exogenous versus Endogenous Gene Therapy
Exogenous and endogenously regulated gene therapies are
each associated with a set of advantages and disadvantages
when considering their use in patients. Firstly, exogenously
regulated systems usually require long-term administration
of a drug. This necessitates extensive characterization of the
safety and tolerability of the drug, which, with the exception
of tetracycline, has not occurred thus far. Additionally, it
is not possible to tailor gene expression precisely to path-
ological signals using exogenous systems unless they are
associated with a noticeable phenotypic change in a timely
manner. In most cases, there is a latent period between
the presence of a pathological signal and the appearance of
clinical symptoms. Therefore, endogenous systems have the
advantage of responding in a timelier manner and with an
intensity that is tailored to the individual patient.
Additionally, gene expression systems are typically ad-
ministered to whole organs or entire regions of organs, and
while it may be advantageous to express transgene in this
manner, this is quite often not the case. By linking transgene
expression to a pathological signal, recombinant protein will
only be produced in cells that require it, and toxic overex-
pression in healthy cells can be avoided. Conversely, a major
limitation of endogenous systems is that once administered
it will be virtually impossible to stop transgene expression in
theeventofanadversereaction,unlessthepopulationofcells
ofinterestisremoved,orthereisabuilt-insafetymechanism.
Additionally, the pathological signals used need to be as far
upstreamaspossible andbespeciﬁctothediseasephenotype
to enable transgene to be expressed in a timely and precise
manner.
6. Conclusions
Regulation of transgene expression remains a key issue lim-
iting widespread clinical application of gene therapies for
CNSdisorders.Oftheexogenousregulationsystemscovered,
tetracycline-regulated systems have been reﬁned suﬃciently
such that they are on the cusp of being applied clinically.
While low basal transgene expression is of concern, in a
clinical setting these levels may not be suﬃcient to elicit a
phenotypic response. Given the advances in gene delivery
technology and the advantages of coupling transgene expres-
sion to a physiological signal, the focus will now be the
development of novel endogenously regulated systems for
use in the CNS.
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